ReviewKidney research and clinical practice2019
Acute kidney injury in the patient with cancer.
Review in Kidney research and clinical practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 71 citations in OpenAlex.
- Prediction of Acute Kidney Injury in Oncology: From Clinical Risk Scores to AI-Enabled Precision Onco-Nephrology.Cancers · 2026Review
- Experimental rodent models of cardiorenal syndrome types 3 and 4: Insights and clinical relevance (Review).International journal of molecular medicine · 2026Review
- The Impact of Aspirin Use on In-Hospital Outcomes and Metastatic Disease in Colorectal Cancer: An Evaluation of the National Inpatient Sample.Journal of clinical medicine · 2026Article
- Application of XGBoost and logistic regression in predicting 90 days mortality for elderly severe acute renal failure patients.Scientific reports · 2026Article
- Acute Kidney Injury in Hospitalized Cancer Patients: Single-Centre Real-Life Analysis of Incidence and Clinical Impact.Journal of clinical medicine · 2026Article
- Article
- Potential Drug Dose-Specific Adverse Three-Drug Combinations: A US Insurance Claims Data-Based Study.Pharmacoepidemiology and drug safety · 2025Article
- Protective effect of deinoxanthin in sorafenib-induced nephrotoxicity in rats with the hepatocellular carcinoma model.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Case Report: Acute kidney injury due to minimal dilated obstructive nephropathy in the context of gastric cancer.Frontiers in oncology · 2025Article
- Toward Model-Based Informed Precision Dosing of Vancomycin in Hematologic Cancer Patients: A First Step.Clinical pharmacokinetics · 2024Article
- Association between phase angle and daily creatinine excretion changes in critically ill patients: an approach to muscle mass.Frontiers in physiology · 2024Article
- Long-term kidney function of childhood cancer survivors-who needs to be monitored?Translational pediatrics · 2023Article
- Macrophage Depletion Protects Against Cisplatin-Induced Ototoxicity and Nephrotoxicity.bioRxiv : the preprint server for biology · 2023Article
- Article
- Impact of Developing Dialysis-Requiring Acute Kidney Injury on Long-Term Mortality in Cancer Patients with Septic Shock.Cancers · 2023Article
- The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage.Cancers · 2023Review
- Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.Cancer communications (London, England) · 2023Review
- Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study.Journal of clinical medicine · 2022Article
- Role of T cells in ischemic acute kidney injury and repair.The Korean journal of internal medicine · 2022Review
- Alleviation of renal ischemia/reperfusion injury by exosomes from induced pluripotent stem cell-derived mesenchymal stem cells.The Korean journal of internal medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dramatic advances in the care of patients with cancer have led to significant improvement in outcomes and survival. However, renal manifestations of the underlying cancer as well as the effects of anti-neoplastic therapies leave patients with significant morbidity and chronic kidney disease risks. The most common renal manifestations associated with cancer include acute kidney injury (AKI) in the setting of multiple myeloma, tumor lysis syndrome, post-hematopoietic stem cell therapy, and AKI associated with chemotherapy. Knowledge of specific risk factors, modification of risk and careful attention to rapid AKI diagnosis are critical for improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.